Search Results - "Krishnamurthi, Smitha S."

5-Fluorouracil Enhances the Antitumor Activity of the Glutaminase Inhibitor CB-839 against PIK3CA -Mutant Colorectal Cancers by Zhao, Yiqing, Feng, Xiujing, Chen, Yicheng, Selfridge, J Eva, Gorityala, Shashank, Du, Zhanwen, Wang, Janet M, Hao, Yujun, Cioffi, Gino, Conlon, Ronald A, Barnholtz-Sloan, Jill S, Saltzman, Joel, Krishnamurthi, Smitha S, Vinayak, Shaveta, Veigl, Martina, Xu, Yan, Bajor, David L, Markowitz, Sanford D, Meropol, Neal J, Eads, Jennifer R, Wang, Zhenghe

“…encodes the p110α catalytic subunit of PI3K and is frequently mutated in human cancers, including ∼30% of colorectal cancer. Oncogenic mutations in render…”
Get full text

Expression of Epiregulin and Amphiregulin and K-ras Mutation Status Predict Disease Control in Metastatic Colorectal Cancer Patients Treated With Cetuximab by KHAMBATA-FORD, Shirin, GARRETT, Christopher R, TAN, Benjamin R, KRISHNAMURTHI, Smitha S, BURRIS, Howard A, POPLIN, Elizabeth A, HIDALGO, Manuel, BASELGA, Jose, CLARK, Edwin A, MAURO, David J, MEROPOL, Neal, BASIK, Mark, HARBISON, Christopher T, SHUJIAN WU, WONG, Tai W, XIN HUANG, TAKIMOTO, Chris H, GODWIN, Andrew K

“…The antiepidermal growth factor receptor (EGFR) antibody cetuximab shows activity in multiple epithelial tumor types; however, responses are seen in only a…”
Get full text

Plasma metabolomic differences in early-onset compared to average-onset colorectal cancer by Jayakrishnan, Thejus, Mariam, Arshiya, Farha, Nicole, Rotroff, Daniel M., Aucejo, Federico, Barot, Shimoli V., Conces, Madison, Nair, Kanika G., Krishnamurthi, Smitha S., Schmit, Stephanie L., Liska, David, Khorana, Alok A., Kamath, Suneel D.

“…Deleterious effects of environmental exposures may contribute to the rising incidence of early-onset colorectal cancer (eoCRC). We assessed the metabolomic…”
Get full text

Racial disparities negatively impact outcomes in early‐onset colorectal cancer independent of socioeconomic status by Kamath, Suneel D., Torrejon, Nataly, Wei, Wei, Tullio, Katherine, Nair, Kanika G., Liska, David, Krishnamurthi, Smitha S., Khorana, Alok A.

“…Background The incidence of colorectal cancer (CRC) in patients under age 50 is rising for unclear reasons. We examined the effects of socioeconomic factors on…”
Get full text

The impact of delayed chemotherapy on its completion and survival outcomes in stage II colon cancer patients by Xu, Fang, Rimm, Alfred A, Fu, Pingfu, Krishnamurthi, Smitha S, Cooper, Gregory S

“…Delayed chemotherapy is associated with inferior survival in stage III colon and stage II/III rectal cancer patients, but similar studies have not been…”
Get full text

Comparison of characteristics and outcomes of young‐onset versus average onset pancreatico‐biliary adenocarcinoma by Jayakrishnan, Thejus, Nair, Kanika G., Kamath, Suneel D., Wei, Wei, Estfan, Bassam N., Krishnamurthi, Smitha S., Khorana, Alok A.

“…Background Young‐onset gastrointestinal malignancies appear to be increasing in incidence. There are limited data on young‐onset pancreaticobiliary…”
Get full text

Expert Commentary on ctDNA Testing for Minimal Residual Disease Assessment and Surveillance by Krishnamurthi, Smitha

Get full text

Multi-omics machine learning to study host-microbiome interactions in early-onset colorectal cancer by Jayakrishnan, Thejus T., Sangwan, Naseer, Barot, Shimoli V., Farha, Nicole, Mariam, Arshiya, Xiang, Shao, Aucejo, Federico, Conces, Madison, Nair, Kanika G., Krishnamurthi, Smitha S., Schmit, Stephanie L., Liska, David, Rotroff, Daniel M., Khorana, Alok A., Kamath, Suneel D.

“…The incidence of early-onset colorectal cancer (eoCRC) is rising, and its pathogenesis is not completely understood. We hypothesized that machine learning…”
Get full text

Colorectal Carcinoma: Overview of Clinical Research and Management 2011 by Krishnamurthi, Smitha S., MD, Meropol, Neal J., MD

Get full text

Clinical Cancer Advances 2016: Annual Report on Progress Against Cancer From the American Society of Clinical Oncology by Dizon, Don S, Krilov, Lada, Cohen, Ezra, Gangadhar, Tara, Ganz, Patricia A, Hensing, Thomas A, Hunger, Stephen, Krishnamurthi, Smitha S, Lassman, Andrew B, Markham, Merry Jennifer, Mayer, Erica, Neuss, Michael, Pal, Sumanta Kumar, Richardson, Lisa C, Schilsky, Richard, Schwartz, Gary K, Spriggs, David R, Villalona-Calero, Miguel Angel, Villani, Gina, Masters, Gregory

Get full text

Preoperative Strategies for Locally Advanced Colon Cancer by Nair, Kanika G., Kamath, Suneel D., Chowattukunnel, Nivan, Krishnamurthi, Smitha S.

“…Opinion statement Neoadjuvant chemotherapy is safe for patients with locally advanced colon cancer (LACC). The FOxTROT trial demonstrated a reduction in…”
Get full text

Phase I Pharmacokinetic and Pharmacodynamic Study of the Oral MAPK/ERK Kinase Inhibitor PD-0325901 in Patients with Advanced Cancers by LORUSSO, Patricia M, KRISHNAMURTHI, Smitha S, RICART, Alejandro D, RINEHART, John J, NABELL, Lisle M, MALBURG, Lisa, CHAPMAN, Paul B, DEPRIMO, Samuel E, BENTIVEGNA, Steven, WILNER, Keith D, WEIWEI TAN

“…To determine tolerability, pharmacokinetics, and pharmacodynamics of PD-0325901, a highly potent, selective, oral mitogen-activated protein…”
Get full text

Evaluation and management of incidental thyroid nodules in patients with another primary malignancy by Wilhelm, Scott M., MD, FACS, Robinson, Ann V., BA, Krishnamurthi, Smitha S., MD, Reynolds, Harry L., MD, FACS

“…Background Studies indicate that incidentally discovered thyroid nodules ≥1 cm in size may have a higher rate of malignancy (7% to 29%) than traditionally…”
Get full text

Phase I Study of Bosutinib, a Src/Abl Tyrosine Kinase Inhibitor, Administered to Patients with Advanced Solid Tumors by DAUD, Adil I, KRISHNAMURTHI, Smitha S, BARDY-BOUXIN, Nathalie, HSYU, Poe-Hirr, LEIP, Eric, TURNBULL, Kathleen, ZACHARCHUK, Charles, MESSERSMITH, Wells A, SALEH, Mansoor N, GITLITZ, Barbara J, BORAD, Mitesh J, GOLD, Philip J, CHIOREAN, Elena G, SPRINGETT, Gregory M, ABBAS, Richat, AGARWAL, Shefali

“…Bosutinib, a potent ATP-competitive, quinolinecarbonitrile Src/Abl kinase inhibitor, was tested in this first-in-human phase I trial in patients with advanced…”
Get full text

Evolving Standards of Care in the Management of Localized Colorectal Cancer by Weinberg, Benjamin A, Sackstein, Paul E, Yu, James, Kim, Richard D, Sommovilla, Joshua, Amarnath, Sudha R, Krishnamurthi, Smitha S

“…The treatment of patients with localized rectal cancer is complex and requires input from a multidisciplinary team. Baseline local staging and mismatch repair…”
Get more information

Phase I clinical trial of temozolomide and methoxyamine (TRC-102), an inhibitor of base excision repair, in patients with advanced solid tumors by Eads, Jennifer R., Krishnamurthi, Smitha S., Saltzman, Joel, Bokar, Joseph A., Savvides, Panos, Meropol, Neal J., Gibbons, Joseph, Koon, Henry, Sharma, Neelesh, Rogers, Lisa, Pink, John J., Xu, Yan, Beumer, Jan H., Riendeau, John, Fu, Pingfu, Gerson, Stanton L., Dowlati, Afshin

“…Summary Temozolomide (TMZ) generates DNA adducts that are repaired by direct DNA and base excision repair mechanisms. Methoxyamine (MX, TRC-102) potentiates…”
Get full text

Association of Inflammatory Biomarkers With Survival Among Patients With Stage III Colon Cancer by Cheng, En, Shi, Qian, Shields, Anthony F, Nixon, Andrew B, Shergill, Ardaman P, Ma, Chao, Guthrie, Katherine A, Couture, Felix, Kuebler, Philip, Kumar, Pankaj, Tan, Benjamin, Krishnamurthi, Smitha S, Ng, Kimmie, O'Reilly, Eileen M, Brown, Justin C, Philip, Philip A, Caan, Bette J, Cespedes Feliciano, Elizabeth M, Meyerhardt, Jeffrey A

“…The association of chronic inflammation with colorectal cancer recurrence and death is not well understood, and data from large well-designed prospective…”
Get more information

A Blueprint to Advance Colorectal Cancer Immunotherapies by Le, Dung T, Hubbard-Lucey, Vanessa M, Morse, Michael A, Heery, Christopher R, Dwyer, Andrea, Marsilje, Thomas H, Brodsky, Arthur N, Chan, Emily, Deming, Dustin A, Diaz, Jr, Luis A, Fridman, Wolf H, Goldberg, Richard M, Hamilton, Stanley R, Housseau, Franck, Jaffee, Elizabeth M, Kang, S Peter, Krishnamurthi, Smitha S, Lieu, Christopher H, Messersmith, Wells, Sears, Cynthia L, Segal, Neil H, Yang, Arvin, Moss, Rebecca A, Cha, Edward, O'Donnell-Tormey, Jill, Roach, Nancy, Davis, Anjelica Q, McAbee, Keavy, Worrall, Sharyn, Benson, Al B

“…Immunotherapy is rapidly becoming a standard of care for many cancers. However, colorectal cancer had been generally resistant to immunotherapy, despite…”
Get more information

A phase I study of MK-5108, an oral aurora a kinase inhibitor, administered both as monotherapy and in combination with docetaxel, in patients with advanced or refractory solid tumors by Amin, Manik, Minton, Susan E., LoRusso, Patricia M., Krishnamurthi, Smitha S., Pickett, Cheryl A., Lunceford, Jared, Hille, Darcy, Mauro, David, Stein, Mark N., Wang-Gillam, Andrea, Trull, Lauren, Lockhart, A. Craig

“…Summary Background MK-5108 is a potent/highly selective Aurora A kinase inhibitor. Methods A randomized Phase I study of MK-5108, administered p.o. BID Q12h on…”
Get full text

A pilot study of a low glycemic load diet in patients with stage I-III colorectal cancer by Treasure, Michelle, Thomas, Alicia, Ganocy, Stephen, Hong, Augustine, Krishnamurthi, Smitha S., Bajor, David L., Berger, Nathan A., Meropol, Neal J.

“…BACKGROUNDConsumption of a diet with high glycemic indices has been associated with inferior cancer-specific outcomes in patients with early-stage colorectal…”
Get full text